[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021]

Essia Mezni; Renaud Sabatier; Anthony Goncalves; Cécile Vicier

doi:10.1016/j.bulcan.2021.12.009

[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021]

Bull Cancer. 2022 Feb;109(2):216-225. doi: 10.1016/j.bulcan.2021.12.009. Epub 2022 Feb 1.

[Article in French]

Authors

Essia Mezni¹, Renaud Sabatier², Anthony Goncalves², Cécile Vicier²

Affiliations

¹ Institut Paoli-Calmettes, université Aix-Marseille, département d'oncologie médicale, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France. Electronic address: meznie@ipc.unicancer.fr.
² Institut Paoli-Calmettes, université Aix-Marseille, département d'oncologie médicale, 232, boulevard de Sainte-Marguerite, 13009 Marseille, France; CRCM-laboratoire d'oncologie prédictive, Inserm U1068, CNRS UMR7258, institut Paoli-Calmettes, université Aix-Marseille, 13009 Marseille, France.

PMID: 35115114
DOI: 10.1016/j.bulcan.2021.12.009

Abstract

Overall, 2021 was marked by the confirmation of the major interest of cell cycle inhibitors for hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative advanced breast cancers with very high overall survival data exceeding five years for hormone-sensitive disease. Studies have also confirmed the efficacy and safety of this therapeutic class in the elderly population. New cell cycle inhibitors are under development (SHR6390). New combinations are also being evaluated, notably palbociclib with SAR439859 (a new selective estrogen receptor degrader: SERD). Targeting of the Phosphoinositide 3-kinases (PI3K) pathway by taselisib, in hormone-resistant disease with a Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) mutation, modestly improves progression-free survival but with a non-negligible toxicity of the treatment.

Keywords: Advanced breast cancer; CDK inhibitor; Cancer du sein métastatique; Hormone receptor-positive; Inhibiteur CDK; Inhibiteur PIK3CA; PIK3CA inhibitor; Récepteurs hormonaux positifs.

Publication types

Review

MeSH terms

Aged
Androstadienes / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Benzamides / therapeutic use
Breast Neoplasms / chemistry
Breast Neoplasms / mortality
Breast Neoplasms / pathology
Breast Neoplasms / therapy*
Class I Phosphatidylinositol 3-Kinases / genetics
Clinical Trials as Topic
Female
Humans
Imidazoles / therapeutic use
Immune Checkpoint Inhibitors / therapeutic use*
Letrozole / therapeutic use
Leuprolide / therapeutic use
Oxazepines / therapeutic use
Phosphoinositide-3 Kinase Inhibitors / therapeutic use
Piperazines / therapeutic use
Progression-Free Survival
Pyridines / therapeutic use
Receptor, ErbB-2
Receptors, Estrogen
Selective Estrogen Receptor Modulators / therapeutic use

Substances

2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
Androstadienes
Antibodies, Monoclonal, Humanized
Benzamides
Imidazoles
Immune Checkpoint Inhibitors
Oxazepines
Phosphoinositide-3 Kinase Inhibitors
Piperazines
Pyridines
Receptors, Estrogen
Selective Estrogen Receptor Modulators
entinostat
Letrozole
pembrolizumab
Class I Phosphatidylinositol 3-Kinases
PIK3CA protein, human
ERBB2 protein, human
Receptor, ErbB-2
Leuprolide
palbociclib
exemestane